Enteric (typhoid) fever is a systemic infection caused by the *Salmonella enterica* serovars Typhi and Paratyphi A, B, and C. Enteric fever is a significant cause of morbidity and mortality in low-income regions \[[@CIT0001]\] and was responsible for an estimated 12.2 million disability-adjusted life-years and \>190 000 deaths globally in 2010 \[[@CIT0002]\]. The fatality rate of enteric fever is low (\<1%) but is higher when antimicrobial therapy is delayed or unavailable \[[@CIT0003]\]. Therefore, antimicrobials are essential for the clinical management of enteric fever. Chloramphenicol, ampicillin, and cotrimoxazole were first-line treatments for enteric fever until the early 1990s when the increasing incidence of multidrug-resistant (MDR; defined as resistance to these 3 antimicrobial drugs) *S.* Typhi organisms led to the use of fluoroquinolones \[[@CIT0004], [@CIT0005]\]. Yet, organisms with reduced susceptibility against fluoroquinolones became a problem in Asia soon after their introduction \[[@CIT0006], [@CIT0007]\]. Recent phylogeographic analyses that document an ongoing epidemic of a global antimicrobial resistance (AMR) *S.* Typhi lineage suggest that the potential for regional or global dispersal of a lineage exhibits resistance to fluoroquinolones is now a real threat \[[@CIT0008]\]. In the absence of effective and accessible vaccines and lack of sanitation improvements, development of tailored antimicrobial therapy recommendations is critical to reduce morbidity and prevent disease transmission.

In Kathmandu, Nepal, *S.* Typhi and *S.* Paratyphi A are the most commonly isolated organisms from the blood of febrile adults and children \[[@CIT0011], [@CIT0012]\]. Over the last decade we conducted 4 randomized, controlled trials (RCTs) to evaluate enteric fever treatment in this endemic region \[[@CIT0013]\]. Our aim in this study was to use the largest collection of individual patient data assembled to date from enteric fever treatment trials to evaluate the effect of treatment drug on differences in clinical outcome between *S.* Typhi and *S.* Paratyphi A infections and those with blood culture-negative enteric fever. We further sought to compare the antimicrobial susceptibility profiles over time between *S.* Typhi and *S.* Paratyphi A isolates and to investigate their impact on outcome. An in-depth understanding of trends and clinical implications of AMR enteric fever should guide policymakers and clinicians in decisions regarding treatment in an era of rapidly diminishing therapeutic options.

MethodS {#s2}
=======

Ethical Approval {#s2a}
----------------

Written informed consent, which was required for participation in all trials, was provided by a parent or adult guardian if a patient was aged \<18 years. The Nepal Health Research Council Ethics Committee and the Oxford Tropical Research Ethics Committee of the United Kingdom provided ethical approval for all 4 studies.

Patient Populations and Study Procedures {#s3}
----------------------------------------

Individual patient data for this study were derived from 4 RCTs conducted at Patan Hospital in Kathmandu, Nepal, between 2005 and 2014, the methods and results of which have been described previously \[[@CIT0013]\]. Patients who presented to the outpatient or emergency department with fever lasting longer than 3 days with a clinical diagnosis of enteric fever (undifferentiated fever \>38°C with no focus of infection) were eligible. Patients were excluded if they were pregnant or lactating, were aged \<2 years or weighed \<10 kg, showed any signs of complications (jaundice, shock, gastrointestinal bleeding), showed hypersensitivity to the relevant trial drugs, or had been treated with a study drug in the week prior to going to the hospital. The study procedures between the 4 trials were comparable; however, there were several minor protocol differences between studies (outlined in Supplementary Table 1).

Patients were randomly assigned to 1 of 2 arms in each trial. Each trial was composed of a gatifloxacin arm (10 mg/kg/day, single dose orally for 7 days) and a comparator arm, which was cefixime (20 mg/kg/day, 2 doses orally for 7 days) \[[@CIT0013]\], chloramphenicol (75 mg/kg/day, 4 divided oral doses for 14 days) \[[@CIT0014]\], ofloxacin (20 mg/kg/day, 2 divided oral doses for 7 days) \[[@CIT0015]\], or ceftriaxone (intravenous; 60 mg/kg for patients aged 2--13 years or 2 g for patients aged ≥14 years) \[[@CIT0016]\]. Gatifloxacin was the constant comparator because it is inexpensive and given once daily.

Fever clearance time (FCT) was defined as the time from the first dose of a study drug until the temperature dropped to ≤37.5°C and remained below this temperature for at least 2 days. The composite endpoint treatment failure summarized unfavorable outcomes and was defined as the occurrence of at least 1 of the following: persistent fever (FCT of more than 7 days \[trials 1 and 4\] or more than 10 days \[trials 2 and 3\] after treatment initiation), the need for rescue treatment, microbiological failure (blood culture positive for *Salmonella*) on day 8, relapse or disease-related complications within 31 days of treatment initiation, or death. Blood was taken from all patients for microbiological culture on enrollment and on day 8 for culture-positive individuals or those with a potential relapse.

Microbiological investigations have been described previously \[[@CIT0013]\]. Blood samples from adult patients were inoculated into media containing tryptone soya broth and sodium polyanethol sulfonate. For children, BacTEC Ped Plus/F bottles were used. Positive bottles were cultured onto MacConkey agar and presumptive *Salmonella* colonies were identified using biochemical tests and serotype-specific antisera. During all 4 trials, minimum inhibitory concentrations (MICs) were determined against the following antimicrobials unless otherwise noted: Augmentin, ampicillin, amoxicillin, azithromycin (2006--2011), cefixime (2005), chloramphenicol, ciprofloxacin (2006--2014), ceftriaxone, gatifloxacin, nalidixic acid, ofloxacin (2006--2014), and cotrimoxazole (2006--2009, 2011--2014), and against tetracycline by E-test (AB Biodisk, Sweden).

Statistical Analyses {#s4}
--------------------

Data from the trials were combined and analyzed using Stata (v 13.1; College Station, Texas). Plots were drawn in R v3.1.1 (R Foundation, Vienna, Austria) using the ggplot2 package. Demographics and clinical variables were tabulated and compared between serovars. Comparisons of clinical parameters between patient populations were structured as logistic regressions with the patient population (either culture positive/negative or *S.* Typhi/*S.* Paratyphi A) as the main covariate and adjustment for age stratum (binary: \<16 years/≥16 years). Multivariable models with random effects were fitted to adjust for study heterogeneity as follows: FCT was evaluated using Kaplan-Meier estimates and Cox proportional hazard models with treatment group and age as covariates; logistic regression was used to determine the odds of treatment failure between treatment arms, controlling for age; and linear regression was used to evaluate the relationship between FCT and log~2~ MIC, also controlling for age. Generalized additive models (GAMs; identity link, cubic spline) were used to examine potential nonlinear trends of MIC over time.

RESULTS {#s5}
=======

Baseline Characteristics {#s6}
------------------------

Between 2005 and 2014 there were 2118 patients with clinically suspected enteric fever randomized into 4 trials; data from 2092 (99%) patients were evaluated ([Figure 1](#F1){ref-type="fig"}). Of these, 855 (41%) were culture positive for either *S.* Typhi (n = 581, 28%) or *S.* Paratyphi A (n = 274, 13%). Throughout the study period there were 139 (6.6%) treatment failures including 1 death. The median patient age was 17 years (interquartile range \[IQR\], 10--23); 66% were male ([Table 1](#T1){ref-type="table"}). There was no significant difference in age between the culture-negative and culture-positive patients; however, *S.* Typhi patients were significantly younger (median, 16 years; IQR, 9--21) than *S.* Paratyphi A patients (median, 19.5 years; IQR, 13--24) (*P* \< .001) ([Table 2](#T2){ref-type="table"}). There was no difference in the sex distribution between culture-positive/culture-negative and *S.* Typhi/*S.* Paratyphi A populations ([Table 2](#T2){ref-type="table"}).

![Enrollment of patients into enteric fever treatment trials in Nepal. Flow chart showing enrollment of patients into the 4 individual, randomized, controlled trials according to antimicrobial treatment and blood culture result.](cix18501){#F1}

###### 

Baseline Characteristics of Patients Enrolled in 4 Enteric Fever Treatment Trials

  **Characteristic**                                  **Trial 1**   **Trial 2**         **Trial 3**   **Trial 4**         **Total**                                                        
  --------------------------------------------------- ------------- ------------------- ------------- ------------------- ----------- ------------------- ----- ------------------- ------ -------------------
  Age (y)                                             382           17 (9--23)          844           16 (9--22)          623         17 (9--23)          239   19 (15--23)         2088   17 (10--23)
  Male sex                                            382           247 (64.7)          844           540 (64.0)          627         406 (64.8)          239   180 (75.3)          2092   1373 (65.6)
  Weight (kg)                                         382           45 (24--53)         842           42 (21--52)         627         45 (25--54)         237   50 (40--56)         2088   45 (24--53)
  Duration of illness before admission (days)         382           5 (3--6)            844           5 (4--7)            625         5 (4--7)            180   5 (4--7)            2031   5 (4--7)
  Treatment with antimicrobials in the past 2 weeks   379           238 (62.8)          724           694 (95.9)          623         428 (68.7)          210   109 (51.9)          1936   1469 (75.9)
  Previous history of typhoid                         382           61 (16.0)           844           138 (16.4)          626         103 (16.5)          238   37 (15.5)           2090   339 (16.2)
  Family history of typhoid                           382           62 (16.2)           844           140 (16.6)          625         164 (26.2)          239   35 (14.6)           2090   401 (19.2)
  Typhoid vaccination                                 382           2 (0.5)             844           0 (0)               625         0 (0)               238   11 (4.6)            2089   13 (0.6)
  Temperature at admission (°C)                       379           38.9 (38.3--39.5)   844           38.9 (38.2--39.4)   626         38.6 (38.2--39.0)   235   38.8 (38.3--39.4)   2084   38.8 (38.2--39.4)
  Headache                                            382           370 (96.9)          844           749 (88.7)          627         541 (86.3)          239   211 (88.3)          2092   1871 (89.4)
  Anorexia                                            382           289 (75.7)          844           632 (74.9)          627         455 (72.6)          239   173 (72.4)          2092   1549 (74.0)
  Abdominal pain                                      382           32 (8.4)            844           33 (3.9)            626         25 (4.0)            235   62 (26.4)           2087   152 (7.3)
  Cough                                               382           142 (37.2)          844           277 (32.8)          627         246 (39.2)          239   91 (38.1)           2092   756 (36.1)
  Nausea                                              382           132 (34.6)          844           258 (30.6)          627         174 (27.8)          239   124 (51.9)          2092   688 (32.9)
  Vomiting                                            382           57 (14.9)           844           172 (20.4)          627         118 (18.8)          239   69 (28.9)           2092   416 (19.9)
  Diarrhea                                            382           86 (22.5)           844           161 (19.1)          627         105 (16.7)          239   59 (24.7)           2092   411 (19.6)
  Constipation                                        382           41 (10.7)           844           105 (12.4)          627         79 (12.6)           239   31 (13.0)           2092   256 (12.2)
  Hepatomegaly                                        382           19 (5.0)            844           113 (13.4)          626         7 (1.1)             231   0 (0)               2083   139 (6.7)
  Splenomegaly                                        382           35 (9.2)            844           119 (14.1)          626         6 (1.0)             231   2 (0.9)             2083   162 (7.8)
  Haematocrit (%)                                     370           40 (37--44)         831           39 (36--43)         624         38 (36--42)         235   39 (36--43)         2060   39 (36--43)
  Leucocyte count (×10^9^/L)                          370           7.0 (5.5--9.0)      831           6.3 (5.0--8.1)      624         6.0 (4.8--7.7)      239   5.9 (4.7--7.3)      2064   6.3 (5.0--8.0)
  Platelet count (×10^9^/L)                           356           190 (160--235)      800           190 (164--226)      615         174 (145--216)      239   168 (150--209)      2010   184 (153--220)
  AST (U/L)                                           373           47 (36--62)         835           45 (34--61)         624         47 (34--67)         233   49 (36--70)         2065   46 (35--65)
  ALT (U/L)                                           373           33 (24--48)         836           29 (20--43)         624         37 (28--53)         234   45 (31--63)         2067   34 (24--50)
  *Salmonella* Typhi isolated                         382           119 (31.2)          844           249 (29.5)          627         132 (21.1)          239   81 (33.9)           2092   581 (27.8)
  *S.* Paratyphi A isolated                           382           50 (13.1)           844           103 (12.2)          627         86 (13.7)           239   35 (14.6)           2092   274 (13.1)
  No growth or culture negative                       382           213 (55.8)          844           492 (58.3)          627         409 (65.2)          239   123 (51.5)          2092   1237 (59.1)

Trials: 1, gatifloxacin/cefixime \[[@CIT0013]\]; 2, gatifloxacin/chloramphenicol \[[@CIT0014]\]; 3, gatifloxacin/ofloxacin \[[@CIT0015]\]; 4, gatifloxacin/ceftriaxone \[[@CIT0016]\].

Abbreviations: ALT, alanine aminotransaminase; AST, asparate aminotransaminase; IQR, interquartile range.

###### 

Demographic and Clinical Characteristics of Culture-Negative, Culture-Positive, *Salmonella* Typhi, and *S* Paratyphi A Patients

  **Characteristic**                                  **Culture Negative**   **Culture Positive**   *P* Value^a^   ***S*. Typhi**    ***S*. Paratyphi A**   *P* Value^a^                                               
  --------------------------------------------------- ---------------------- ---------------------- -------------- ----------------- ---------------------- -------------- ----------------- ----- ------------------- --------
  Age (y)^b^                                          1236                   17 (9--24)             852            17 (10--22)       .692                   578            16 (9--21)        274   19.5 (13--24)       \<.001
  Male sex^b^                                         1237                   818 (66.1)             855            555 (64.9)        .565                   581            373 (64.2)        274   182 (66.4)          .525
  Weight (kg)                                         1234                   44 (23--54)            854            46 (25--53)       .854                   580            43.5 (22--52)     274   49 (38--55)         \<.001
  Duration of illness before admission (days)         1203                   5 (4--7)               828            5 (4--7)          .500                   565            5 (4--7)          263   5 (4--6)            .102
  Treatment with antimicrobials in the past 2 weeks   1146                   861 (75.1)             790            608 (77.0)        .330                   532            414 (77.8)        258   194 (75.2)          .440
  Previous history of typhoid                         1236                   208 (16.8)             854            131 (15.3)        .276                   581            68 (11.7)         273   63 (23.1)           \<.001
  Family history of typhoid                           1236                   242 (19.6)             854            159 (18.6)        .657                   580            107 (18.4)        274   52 (19.0)           .400
  Typhoid vaccination                                 1234                   9 (0.7)                855            4 (0.5)           .511                   581            1 (0.2)           274   3 (1.1)             .073
  Temperature at admission (°C)                       1233                   38.7 (38.1--39.2)      851            39 (38.4--39.5)   \<.001                 577            39 (38.5--39.5)   274   38.8 (38.2--39.2)   \<.001
  Headache                                            1237                   1098 (88.8)            855            773 (90.4)        .348                   581            518 (89.2)        274   255 (93.1)          .237
  Anorexia                                            1237                   903 (73.0)             855            646 (75.6)        .190                   581            451 (77.6)        274   195 (71.2)          .036
  Abdominal pain                                      1237                   479 (38.7)             855            258 (30.2)        .067                   581            261 (44.9)        274   97 (35.4)           .061
  Cough                                               1237                   495 (40.0)             855            261 (30.5)        \<.001                 581            193 (33.2)        274   68 (24.8)           .011
  Nausea                                              1237                   394 (31.9)             855            294 (34.4)        .310                   581            198 (34.1)        274   96 (35.0)           .853
  Vomiting                                            1237                   271 (21.9)             855            145 (17.0)        .010                   581            106 (18.2)        274   39 (14.2)           .324
  Diarrhea                                            1237                   210 (17.0)             855            201 (23.5)        \<.001                 581            161 (27.7)        274   40 (14.6)           \<.001
  Constipation                                        1237                   154 (12.4)             855            102 (11.9)        .775                   581            63 (10.8)         274   39 (14.2)           .114
  Hepatomegaly                                        1234                   84 (6.8)               849            55 (6.5)          .847                   578            40 (6.9)          271   15 (5.5)            .804
  Splenomegaly                                        1234                   85 (6.9)               849            77 (9.1)          .069                   578            48 (8.3)          271   29 (10.7)           .224
  Hematocrit (%)                                      1219                   39 (36--43)            841            39 (36--43)       .573                   569            39 (35--43)       272   40 (37--44)         .006
  Leucocyte count (×109/L)                            1220                   6.4 (5.0--8.6)         844            6.1 (4.9--7.5)    \<.001                 572            6.2 (4.9--7.5)    272   5.8 (4.8--7.2)      .528
  Platelet count (×109/L)                             1187                   187 (157--229)         823            180 (150--210)    .002                   555            180 (151--214)    268   180 (150--210)      .469
  AST (U/L)                                           1220                   42 (32--59)            845            51 (40--69)       \<.001                 573            54 (42--71)       272   47 (37.5--66)       .023
  ALT (U/L)                                           1220                   31 (21--46.5)          847            38 (28--53)       \<.001                 575            39 (28--53)       272   36 (28--49.5)       .564

Abbreviations: IQR, interquartile range; AST, asparate aminotransaminase; ALT, alanine aminotransaminase.

^a^ *P* values derived from logistic regression (categorical variables) or linear regression (continuous variables) with outcome characteristic of interest and a covariate of culture positivity or serovar, controlling for age (\<15 years/≥16 years).

^b^ *P* values derived using Fisher exact test for categorical data and the Kruskal-Wallis test for continuous data (not controlled for age).

There were several significant differences in clinical history between patient populations after controlling for age ([Table 2](#T2){ref-type="table"}). Culture-negative patients were significantly more likely to report coughing (40%) and vomiting (22%) than culture-positive patients (31% and 17%, respectively). Culture-positive patients, however, reported diarrhea (24%) more often than culture-negative patients (17%) in addition to a higher temperature (median, 39.0°C and 38.7°C, respectively). Among the culture-positive patients, those with an *S.* Typhi infection were significantly more likely to report a history of anorexia (78%), coughing (33%), and diarrhea (28%) compared to the *S.* Paratyphi A patients (71%, 25%, and 15%, respectively) and presented with higher temperatures (median, 39.0°C vs 38.8°C). *Salmonella* Paratyphi A patients were significantly more likely to report a history of previous typhoid illness (23%) compared to *S.* Typhi patients (12%). Additionally, there were several significant differences in hematology parameters between the culture-negative/culture-positive patients and the *S.* Typhi/*S.* Paratyphi A patients ([Table 1](#T1){ref-type="table"}), despite the majority of the values falling within normal ranges. Asparate aminotransaminase and alanine aminotransaminase were significantly elevated in the culture-positive patients (median, 51 U/L and median, 38 U/L, respectively) compared to culture-negative patients (median, 42 U/L and median, 31 U/L, respectively).

Treatment Failure {#s7}
-----------------

The number of patients who failed treatment in each treatment arm is shown in [Table 3](#T3){ref-type="table"}. Failure rates between antimicrobial treatment arms were largely similar when stratified by microbiological culture result, with a few notable exceptions. Compared to gatifloxacin, culture-positive patients were significantly more likely to fail treatment when administered cefixime (odds ratio \[OR\], 10.7; 95% confidence interval \[CI\], 3.72--30.61; *P* \< .001). Culture-negative patients were more likely to fail with cefixime (OR, 7.13; 95% CI, 2.82--18.0; *P* \< .001), ceftriaxone (OR, 19.3; 95% CI, 8.02--46.5; *P* \< .001), and chloramphenicol (OR, 3.67; 95% CI, 1.52--8.86; *P* = .004) compared to gatifloxacin.

###### 

Proportion of Enteric Fever Patients With Treatment Failure by Culture Result and Treatment

  **Treatment Arm**   **Culture Negative**   **Culture Positive**   ***Salmonella* Typhi**   ***Salmonella* Paratyphi A**                           
  ------------------- ---------------------- ---------------------- ------------------------ ------------------------------ ----- ----------- ----- ----------
  Gatifloxacin        617                    9 (1.5)                440                      36 (8.2)                       298   26 (8.7)    142   10 (7.0)
  Cefixime            105                    10 (9.5)               77                       26 (33.8)                      54    19 (35.2)   23    7 (30.4)
  Ceftriaxone         65                     15 (23.1)              54                       4 (7.4)                        38    3 (7.9)     16    1 (6.3)
  Chloramphenicol     243                    12 (4.9)               175                      14 (8.0)                       125   11 (8.8)    50    3 (6.0)
  Ofloxacin           207                    5 (2.4)                109                      8 (7.3)                        66    7 (10.6)    43    1 (2.3)

Fever Clearance Times {#s8}
---------------------

The FCTs of the various patient populations are shown in [Figure 2](#F2){ref-type="fig"} and [Table 4](#T4){ref-type="table"}. Among the culture-positive patient population, *S.* Typhi patients treated with cefixime (hazard ratio \[HR\], 0.36; 95% CI, 0.25--0.54; *P* \< .001) and ceftriaxone (HR, 1.53; 95% CI,1.01--2.31; *P* = .043) had significantly longer FCTs than *S.* Typhi patients treated with gatifloxacin. In the culture-positive patients, those infected with *S.* Typhi also had significantly longer FCTs than *S.* Paratyphi A patients when treated with cefixime (HR, 2.18; 95% CI,1.25--3.80; *P* = .006; [Table 4](#T4){ref-type="table"}). However, *S.* Paratyphi A--infected patients had longer FCTs when treated with chloramphenicol compared to *S.* Typhi--infected patients (HR, 0.069; 95% CI, 0.49--0.97; *P* = .031). Compared to gatifloxacin, culture-negative patients fared significantly worse when treated with cefixime (HR, 0.56; 95% CI, 0.43--0.71; *P* \< .001) and ceftriaxone (HR, 0.42, 95% CI, 0.31--0.57; *P* \< .001).

![Fever clearance time (FCT) by treatment arm and culture result. FCT (in days) is shown for *Salmonella* Typhi, *S.* Paratyphi A, and culture-negative patients. Colors indicate the different treatment arms. Abbreviations: CFX, cefixime; CHL, chloramphenicol; CRO, ceftriaxone; GAT, gatifloxacin; OFX, ofloxacin.](cix18502){#F2}

###### 

Fever Clearance Time (in hours) for 4 Enteric Fever Patient Populations by Treatment

  **Population**   **Culture Negative**   **Culture Positive**   ***Salmonella* Typhi**   ***Salmonella* Paratyphi A**                                                                                                             
  ---------------- ---------------------- ---------------------- ------------------------ ------------------------------ --------------------- ------------- ----- --------------------- ------------- ----- --------------------- -------------
  Overall          1178                   41.3 (18.2--71.3)      1.0--425.5               810                            92.7 (65.3--124.7)    1.0--496.0    549   92.0 (66.4--125)      1.0--496.0    261   94.4 (56.1--122.8)    1.0--349.0
  Treatment arm                                                                                                                                                                                                                    
  GAT              585                    39.1 (17.0--68.0)      1.0--285.9               416                            90.9 (64.3--116.9)    1.0--349.0    283   90.8 (67.4--117.3)    1.0--309.6    133   91.9 (55.8--116.0)    6.8--349.0
  CFX              96                     66.5 (18.5--134.5)     4.0--324.0               69                             134.0 (82.0--205.0)   16.0--496.0   47    140.0 (96.0--232.0)   40.0--496.0   22    100.0 (81.0--164.0)   16.0--214.0
  CRO              62                     102.3 (31.5--161.5)    1.0--354.3               54                             73.5 (46.0--112.8)    7.8--232.8    38    82.6 (54.0--117.5)    7.8--215.4    16    53.1 (43.3--83.0)     7.8--232.8
  CHL              239                    41.5 (20.2--68.7)      1.0--304.5               169                            94.2 (65.2--136.3)    2.8--327.4    120   89.8 (65.2--121.7)    2.8--327.4    49    114.7 (63.4--151.6)   4.4--262.8
  OFX              196                    36.8 (17.9--66.4)      1.0--425.5               102                            94.8 (56.0--122.3)    1.0--311.8    61    89.8 (48.0--115.4)    3.6--189.8    41    104.4 (71.5--141.6)   1.0--311.8

Abbreviations: CFX, cefixime; CHL, chloramphenicol; CRO, ceftriaxone; FCT, fever clearance time; GAT, gatifloxacin; IQR, interquartile range; OFX, ofloxacin.

Antimicrobial Susceptibility Trends {#s9}
-----------------------------------

As shown in [Figure 3](#F3){ref-type="fig"}, the MICs for *S.* Paratyphi A were significantly higher than those for *S.* Typhi with all antimicrobials (*P* \< .001, Kruskal-Wallis), with the exception of cefixime (*P* = .375). [Figure 4](#F4){ref-type="fig"} shows the MIC time trends by serovar, which were significantly nonlinear over time for all antimicrobials in both serovars (GAM, *P* \< .001 with the exception of *S.* Paratyphi A/ciprofloxacin \[*P* = .052\] and *S.* Paratyphi A/nalidixic acid \[*P* = .003\]). Most notably, the MICs against the fluoroquinolones rose significantly over time, and the MICs against azithromycin declined between 2007 and 2010. Last, all isolates were susceptible to ceftriaxone throughout the study period.

![Distribution of minimum inhibitory concentrations (MICs) against antimicrobials for *Salmonella* Typhi and *S*. Paratyphi A. MICs shown on a log~2~ scale against 12 antimicrobials for *S*. Typhi (blue) and *S*. Paratyphi A (orange). Lower, middle, and upper horizontal dashed lines represent the current Clinical and Laboratory Standards Institute cutoffs for susceptible/intermediate and intermediate/resistant, respectively.](cix18503){#F3}

![Minimum inhibitory concentrations (MICs) over time for *Salmonella* Typhi and *S.* Paratyphi A. MICs shown on a log~2~ scale for 8 antimicrobials over the period 2005--2014. *Salmonella* Typhi are shown in blue and *S.* Paratyphi A are shown in orange. The smoothed line is derived from the generalized additive model showing a nonlinear increase in MICs over time, with the shaded region showing the 95% confidence interval. Lower, middle, and upper horizontal dashed lines represent the current Clinical and Laboratory Standards Institute cutoffs for susceptible/intermediate and intermediate/resistant, respectively.](cix18504){#F4}

Impact of Antimicrobial Resistance on Clinical Outcomes {#s10}
-------------------------------------------------------

Increasing MICs against fluoroquinolones led to longer FCTs in *S.* Typhi patients. As shown in [Figure 5](#F5){ref-type="fig"}, an increasing (log~2~) MIC was associated with longer FCTs in patients treated with gatifloxacin (number of hours increase in FCT for each 2-fold increase in MIC (β = 8.1; 95% CI, 5.3--10.8; *P* \< .001) and ofloxacin (β = 8.4; 95% CI, 2.2--14.5; *P* = .008). Longer FCTs were also observed with increasing MICs against ciprofloxacin in *S.* Typhi patients treated with ofloxacin or gatifloxacin (β = 6.88; 95% CI, 4.9--8.9; *P* \< .001). However, we found no significant association between FCT and (log~2~) MIC against the fluoroquinolones in the *S.* Paratyphi A patients (all *P* \> .05). Additionally, there was no significant association between FCT and MIC for the other antimicrobials tested. Last, patients infected with an *S.* Typhi isolate that was nonsusceptible to ciprofloxacin (MIC ≥0.12 μg/mL) were more likely to experience treatment failure (29/211, 13.7%) when treated with ofloxacin or gatifloxacin compared to patients infected with *S.* Typhi organisms susceptible to ciprofloxacin (MIC \< 0.12 μg/mL; 2/79, 2.5%; OR, 5.16; 95% CI, 1.1--23.2; *P* = .033). Conversely, we did not identify a similar relationship in those infected with *S.* Paratyphi A (8/149 \[5.4%\] vs 1/6 \[16.7%\]; OR, 0.32; 95% CI, 0.03--3.15; *P* = .329), the majority of which exhibited reduced susceptibility against ciprofloxacin (MIC ≥0.12 μg/mL; 211/221, 96%).

![Fever clearance time and minimum inhibitory concentrations (MICs) against fluoroquinolones for *Salmonella* Typhi and *S.* Paratyphi A. Fever clearance time (in days) is shown plotted against log~2~ MIC for gatifloxacin (left) and ofloxacin (right). *Salmonella* Typhi isolates are shown in blue and *S.* Paratyphi A isolates are shown in orange. The lines represent the best-fit linear model, with 95% confidence interval shown by the shaded region.](cix18505){#F5}

DISCUSSION {#s11}
==========

Enteric fever remains the leading cause of febrile bacterial illness in Kathmandu \[[@CIT0012]\]. With alarming AMR rates, a lack of immunization as a public health tool, and slow sanitation improvements, tailored antimicrobial therapies for the prevailing AMR profiles are required. Using systematic, longitudinal, individual patient data, we identified dynamic antimicrobial susceptibility profiles among *S.* Typhi and *S.* Paratyphi A isolates and a trend of increasing fluoroquinolone MICs correlating with poor outcome. This phenomenon was particularly apparent among *S.* Typhi patients. Although ceftriaxone was effective in treating culture-confirmed enteric fever patients, we documented poor clinical response in culture-negative patients. These data suggest that careful consideration is required for antimicrobial therapy of patients with enteric fever. In addition, fluoroquinolones should not be recommended for empirical treatment of this infection in South Asia \[[@CIT0017]\].

By combining the largest number of enteric fever patients from a single location, we were able to identify several notable differences in both clinical presentation and clinical response between *S.* Typhi and *S.* Paratyphi A patients. Previous work conducted at the same center showed the 2 serovars to be clinically indistinguishable \[[@CIT0018]\]. We found that, after controlling for age, *S.* Typhi patients were more likely to report anorexia, diarrhea, and coughing and presented with a higher temperature.

The precise mechanism driving the variability in MICs over time for both *S*. Typhi and *S.* Paratyphi A against several antimicrobials throughout 2005--2014 is unknown but may be determined by local prescribing practices. This hypothesis is consistent with notable declines in MDR organisms in both Nepal and India after fluoroquinolones became the first choice of treatment \[[@CIT0012], [@CIT0019], [@CIT0020]\]. However, we predict a rapid rebound of MDR organisms with reversion to the prescribing of first-line antimicrobials due to the circulation of MDR plasmids in *S*. Typhi and other organisms \[[@CIT0008], [@CIT0021]\].

Our study period captured dynamic changes in MICs against fluoroquinolones, particularly among *S.* Typhi isolates in more recent years. Through whole genome sequencing, we have determined that this rise in MIC is associated with the emergence of an H58 variant with mutations in the DNA gyrase gene (*gyrA*) and the DNA topoisomerase IV gene (*parC*) \[[@CIT0010], [@CIT0016]\]. Supporting these findings, we can conclusively show that FCTs and the rate of treatment failure increases with elevated MICs in *S.* Typhi patients treated with a fluoroquinolone, confirming results from small studies conducted elsewhere \[[@CIT0007], [@CIT0022]\]. However, although *S.* Paratyphi A isolates had significantly higher MICs against all tested fluoroquinolones in comparison to *S.* Typhi, poor outcome was not significantly associated with increasing MIC. We suggest continued surveillance of *S.* Paratyphi A in the region to monitor for the emergence of high-level fluoroquinolone-resistant organisms similar to trends in the *S*. Typhi population.

As highlighted in our most recent RCT, patients with suspected enteric fever who were blood culture negative were treated effectively with gatifloxacin, yet fared less well when treated with ceftriaxone \[[@CIT0016]\]. The present analysis shows that ofloxacin also performs well in treating those with culture-negative enteric fever. However, due to the low sensitivity of blood culture for the detection of *S.* Typhi and *S.* Paratyphi A\[[@CIT0023]\], it is likely ofloxacin may have been effective against undetected enteric fever cases. We have documented that a reasonable proportion (22%, 21/96) of patients enrolled in the third trial included in the present analysis \[[@CIT0014]\] who were blood culture negative were serologically positive for murine typhus \[[@CIT0024]\]. Doxycycline is considered the drug of choice for rickettsial infections, although it seems that fluoroquinolones may also have clinical activity \[[@CIT0024]\].

In 2003 the World Health Organization published guidelines that recommended azithromycin, ceftriaxone, or cefixime for quinolone-resistant *S.* Typhi and *S.* Paratyphi A infections \[[@CIT0023]\]. Azithromycin is safe and efficacious for the treatment of uncomplicated typhoid \[[@CIT0025], [@CIT0026]\]. Although there are no current clinical MIC breakpoints, the majority of isolates (88%) here were susceptible, using the previously suggested cutoff of \<16 µg/mL \[[@CIT0027]\]. The low MICs against ceftriaxone and rapid FCTs throughout the study period indicate that this drug is likely to be effective for culture-confirmed enteric fever in Nepal. The cost and parenteral route of administration, however, make ceftriaxone less suitable for patient treatment in low- and middle-income countries, particularly as 60%--90% of enteric fever patients are treated as outpatients \[[@CIT0003]\]. An alternative would be the oral, third-generation cephalosporin cefixime. However, our first trial, in which we compared gatifloxacin with cefixime, had to be stopped early by the Data Safety Monitoring Board because of the high failure rate in the cefixime arm (26/77) compared to the gatifloxacin arm (5/92; OR, approximately 9), despite all strains being cefixime susceptible \[[@CIT0013]\]. Our analysis supports a recommendation for azithromycin or ceftriaxone for culture-confirmed enteric fever, and in the absence of rapid diagnostics for rickettsial infections \[[@CIT0028]\], a combination of ceftriaxone and doxycycline in culture-negative febrile patients in this setting \[[@CIT0016]\]. However, identification of extended-spectrum β-lactamase--producing *S.* Paratyphi A in India again suggests vigilance is required.

Our study has limitations. First, the poor diagnostic sensitivity of blood culture may lead to misclassification of a significant number of patients. Although a proportion of culture negatives are likely to be positive for *Rickettsia* spp., this was not directly assessed \[[@CIT0024]\]. Furthermore, by combining patients from individual RCTs with some differing definitions, the data became nonrandomized; however, we included a random effect of study to account for heterogeneity between studies and controlled for age. Therefore, strong associations, such as odds of treatment failure between cefixime and gatifloxacin in culture-positive patients, may be reduced with the larger, nonrandomized data. Additionally, we were unable to access pharmacy records to evaluate the relationship of prescribing patterns for febrile patients and MICs against common antimicrobials. Notwithstanding these limitations, the results from this largest collection of trials with patient recruitment spanning a decade in an endemic location with a high burden of disease will help to inform therapy recommendations.

In conclusion, poor sanitation, low vaccine uptake, and the emergence of extensive ciprofloxacin-resistant *S.* Typhi in Kathmandu suggest that appropriate antimicrobial usage policies are required in order to limit morbidity, mortality, and transmission. In this large evaluation, we document shifting antimicrobial susceptibility profiles, an association between poor treatment outcome, and *S.* Typhi MICs in patients treated with a fluoroquinolone and again highlight the need for better diagnostics for febrile diseases in this setting. We reiterate that fluoroquinolones should not be recommended for the empirical treatment of enteric fever in South Asia \[[@CIT0008], [@CIT0029]\] and advocate the use of azithromycin or ceftriaxone, in addition to surveillance for changes in AMR profiles.
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